<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03468348</url>
  </required_header>
  <id_info>
    <org_study_id>SECI-IRB-IORG0006563-437</org_study_id>
    <nct_id>NCT03468348</nct_id>
  </id_info>
  <brief_title>Duloxetine for Acute Post-mastectomy Pain</brief_title>
  <official_title>Duloxetine for Acute Post-mastectomy Pain: Placebo Controlled Dose Ranging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the analgesic effect of oral dulexitine tablet
      (administered 2 h before surgery) as well as the ideal dose for acute postmastectomy pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      patients undergoing mastectomy with axillary evacuation will be divided to four groups,
      Placebo group: received placebo capsule Duloxetine 30: received duloxetine 30 mg capsule
      Duloxetine 60: received duloxetine 60 mg capsule Duloxetine 90: received duloxetine 90 mg
      capsule the study medication is administered orall 2 h before surgery. Primary outcome
      variable: the first postoperative 24 h morphine consumption Secondary outcome: the VAS pain
      score measured every 4 h in the first 24 h postoperatively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Actual">February 10, 2020</completion_date>
  <primary_completion_date type="Actual">February 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the first postoperative 24 h (patient controlled analgesia [PCA])morphine consumption</measure>
    <time_frame>the first postoperative 24 hour</time_frame>
    <description>the cumulative patient controlled analgesia morphine consumption required by the patients to relieve their pain in the first postoperative 24 h</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The intensity of pain measured by visual analogue pain scale (VAS)</measure>
    <time_frame>The outcome will be assessed at 0 hour, 2 hour, 4 hour,8 hour, 16 hour and 24 hour postoperatively.</time_frame>
    <description>The intensity of pain measured by visual analogue pain scale (VAS) in which 0 = no pain and 10 = the maximum imaginable pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The quality of postoperative recovery, assessed by &quot;The QoR-40 questionnaire&quot; (the quality of recovery-40 questionnaire)</measure>
    <time_frame>the questionnair will be assessed once, 24 hour postoperatively</time_frame>
    <description>It measures five components of patient recovery: physical comfort (12 questions), physical independence (5 questions), emotional state (9 questions), psychological support (7 questions), and pain (7 questions). The sum of each component generates an aggregate score that ranges from 40 (i.e., extremely poor quality of recovery) to 200 (i.e., excellent quality of recovery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of consciousness assessed by &quot;the Modified Ramsay Sedation score&quot;</measure>
    <time_frame>the score will be measured at 8 hour, 16 hour and 24 hour postoperatively</time_frame>
    <description>awake levels were: I = anxious, agitated, or restless; II = cooperative, oriented, and tranquil; III = responds to command, and asleep levels were dependent on patient's response to a light glabellar tap or loud auditory stimulus; IV= brisk response; V = a sluggish response; and VI = no response)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The occurrence of vomiting</measure>
    <time_frame>The outcome will be obtained once 24 hour postoperatively</time_frame>
    <description>vomiting is forceful discharge of stomach contents</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>duloxetine 30</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>duloxetine 60</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>duloxetine 90</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>patients scheduled for mastectomy and axillary evacuation for cancer breast will receive orally, 2 hours before the operation either, placebo capsule, duloxetine 30 mg,duloxetine 60 mg or duloxetine 90 mg capsule.</description>
    <arm_group_label>duloxetine 30</arm_group_label>
    <arm_group_label>duloxetine 60</arm_group_label>
    <arm_group_label>duloxetine 90</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult females scheduled for unilateral MRM with axillary evacuation for breast cancer,

          -  American Society of Anesthesiologists physical status (ASA) class I and II

        Exclusion Criteria:

          -  Patients with a known allergy to Duloxetine or morphine,

          -  A history of drug or alcohol abuse,

          -  Patients with impaired kidney or liver functions,

          -  Patients with chronic pain or regularly receiving analgesics,

          -  Any psychiatric illness that would interfere with the perception and the assessment of
             pain.

          -  Any reason that resulted in the protocol violation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Diab</name>
      <address>
        <city>Assiut</city>
        <state>Assuit</state>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 11, 2018</study_first_submitted>
  <study_first_submitted_qc>March 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Diab Fuad Hetta</investigator_full_name>
    <investigator_title>principle investigator</investigator_title>
  </responsible_party>
  <keyword>duloxetine</keyword>
  <keyword>mastectomy</keyword>
  <keyword>postoperative pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

